Investor Relations

News Releases

Webcast
Apadaz Update Call
Friday, February 23, 2018 at 2:30 PM EST
Date Title
02/23/18
Summary ToggleKemPharm Announces FDA Approval of Apadaz™ (benzhydrocodone and acetaminophen) for the Short-Term Management of Acute Pain Apadaz is the First Prodrug of Hydrocodone/Acetaminophen to be Approved by FDA Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 2:30 p.m. ET CORALVILLE, Iowa , Feb. 23, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company
02/13/18
Summary ToggleKemPharm to Present at the RBC Capital Markets 2018 Global Healthcare Conference Corporate Updates and Clinical Progress to be Highlighted CORALVILLE, Iowa , Feb. 13, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that the Company’s
01/31/18
Summary ToggleKemPharm to Present at The MoneyShow Orlando Investor Conference CORALVILLE, Iowa , Jan. 31, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that its President and Chief Executive Officer, Travis C.
01/23/18
Summary ToggleKemPharm Receives Patent Grant for KP606, a Prodrug of Oxycodone Additional Patent Granted for the KP511-related family, a Prodrug of Hydromorphone CORALVILLE, Iowa , Jan. 23, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today
01/08/18
Summary ToggleKemPharm Initiates Pivotal Efficacy Trial of KP415 ‘Classroom-style’ Pivotal Efficacy Trial of ADHD Prodrug Composition Candidate  to Study Onset and Duration of Efficacy and Product Safety Screening commenced in November; first patient treatment occurred December 20, 2017 CORALVILLE, Iowa , Jan. 08, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc.
11/16/17
Summary ToggleKemPharm Completes Successful End-of-Phase 2 Meeting on KP415 with FDA All Clinical and Non-Clinical Programs Remain on Track for ADHD Prodrug Candidate,  Pivotal Efficacy Trial to Study Duration of Therapy to Initiate Prior to Year-End CORALVILLE, Iowa , Nov. 16, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company
11/09/17
Summary ToggleKemPharm Reports Third Quarter 2017 Results and Provides Corporate Update Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development & Regulatory Highlights: Filed IND for KP484, A Super-Extended Release ADHD Methylphenidate Prodrug Product Candidate --  KP484 IND Review Completed by FDA ; Cleared to Proceed to Clinical
11/06/17
Summary ToggleKemPharm Receives USAN Approval for “Asalhydromorphone” as Nonproprietary Name for Novel Prodrug Candidate, KP511 Asalhydromorphone’s Physicochemical and Pharmacological Attributes May Offer the Potential to Provide Significant Pain Relief with the Potential of Reduced Opioid Abuse and Misuse CORALVILLE, Iowa , Nov. 06, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc , a clinical-stage specialty pharmaceutical company
11/02/17
Summary ToggleKemPharm’s KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate, Allowed to Proceed to Clinical Studies KP484 Designed to be a Predictably Dosed, “ Super-Extended” Release, Methylphenidate Product Candidate CORALVILLE, Iowa , Nov. 02, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc , a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced
11/01/17
Summary ToggleKemPharm, Inc. to Report Third Quarter 2017 Results Conference Call and Live Audio Webcast with Slide Presentation Scheduled for  November 9, 2017 , 4:30 p.m. ET CORALVILLE, Iowa , Nov. 01, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary
10/04/17
Summary ToggleKemPharm and Genco Sciences Announce Technology Licensing Agreement to Develop Prodrug-Based Therapy for Potential Rare Pediatric Indications of Tourette’s Syndrome with ADHD Agreement May Lead to Addition of New Drug Product Candidate and Indication to KemPharm’s Prodrug Development Pipeline CORALVILLE, Iowa , Oct. 04, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of
09/20/17
Summary ToggleKemPharm Files IND for KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate KP484 Designed to be a Predictably Dosed, Super-Extended Release, Methylphenidate Product CORALVILLE, Iowa , Sept. 20, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, 
09/12/17
Summary ToggleKemPharm Announces FDRR Process Completion and Resubmission of the Apadaz™ NDA FDA Has Assigned a PDUFA Action Date of February 23, 2018 Conference Call and Live Audio Webcast Today at 8:30 a.m. ET CORALVILLE, Iowa , Sept. 12, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of
08/31/17
Summary ToggleKemPharm to Present at the Rodman & Renshaw 19th Annual Global Investment Conference CORALVILLE, Iowa , Aug. 31, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs,  announced today that its President and Chief Executive Officer, Travis C.
08/10/17
Summary ToggleKemPharm, Inc. Reports Second Quarter 2017 Results Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Clinical Development & Regulatory Highlights : KP415.109 Pharmacokinetics Phase 1 Trial Completed Held KP415 End-of-Phase 1 Meeting with U.S. Food and Drug Administration ( FDA ) Initiated
08/10/17
Summary ToggleKemPharm Announces Preliminary Results from KP415 Pharmacokinetic Single and Multiple Dose Trial Phase I Study Results Demonstrated Early Peak Exposure to d-Methylphenidate followed by Sustained Duration in both Single and Multiple Dose Settings CORALVILLE, Iowa , Aug. 10, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the
08/08/17
Summary ToggleKemPharm Announces Publication of Study of Intranasal Abuse of Hydrocodone Combination Products in Pharmacoepidemiology & Drug Safety Study Confirms Intranasal Abuse of Hydrocodone/Acetaminophen by Adolescents & Adults may be a Significant Public Health Issue CORALVILLE, Iowa , Aug. 08, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and
08/03/17
Summary ToggleKemPharm to Present at Canaccord Genuity 37th Annual Growth Conference CORALVILLE, Iowa , Aug. 03, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C.
08/01/17
Summary ToggleKemPharm, Inc. to Report Second Quarter 2017 Results Conference Call and Live Audio Webcast with Slide Presentation Scheduled for August 10, 2017 , 4:30 p.m. ET CORALVILLE, Iowa , Aug. 01, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary
06/28/17
Summary ToggleKemPharm Strengthens ADHD Prodrug Pipeline with Development of KP484, A New, Super-Extended Release ADHD Methylphenidate Product Candidate KP415 End-of-Phase 1 Meeting with FDA Affirms KemPharm’s Development Plan and Potential NDA Submission as early as late 2018 Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET CORALVILLE, Iowa , June 28, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc.